Thomas Lingelbach: Our objective is to have a clinical entry by the end of this year, very, very early next year, but it’s one programs or two programs. It’s still something that we’re going to decide out of our own pipeline, but we will definitely informed markets, which program is we are expecting to enter into clinics. So, this would certainly be a new for this year. And then, we have this ongoing point about reviewing potential additional external opportunities to inject in our clinical pipeline since we have clinically relevant capacity and capability. And that’s certainly an ongoing process as reported in the expected news flow and catalyst section.
Operator: Thank you. We will now take the next question. It comes from the line of Rajan Sharma from Goldman Sachs. Please go ahead. Your line is open.
Rajan Sharma: Hi, thanks for taking my additional questions. I just wanted to follow-up on the BD M&A piece or the external kind of sources of innovation. Would your preference on that be kind of a knowledge platform that you potentially don’t have in house right now, or would you be looking at specific assets? And then, just secondly, just to follow-up again, on my initial question on kind of volume versus price, so I was just wondering, I guess I could ask in a different way, were you able to kind of take price increases on DUKORAL third-party products on IXIARO in 2022, and do you expect to be able to do that in 2023? Thank you.
Thomas Lingelbach: Yes, thanks, Rajan. Let me start with your second question. So, yes, we did increase pricing across the board for basically most — IXIARO — those are some of our third-party products. And we of course are also looking at continuous electric price increases in certain countries going forward.
Peter Buhler: Can you repeat your first question, please?
Rajan Sharma: Also, just in terms of kind of external sources of —
Peter Buhler: Okay, the external influx in that, so basically I mean you know that Valneva is technology agnostic company, right. So, we are not a technology company we have, we go by indication, we go by indication where we are looking into indications where we can still play a pioneering role I mentioned earlier, first only bet. Valneva has historically worked with literally all vaccine technologies out there except mRNA. Of course, we will also be open to work on a specific indication on mRNA, but it’s not our interest to acquire a technology company or a technology platform or going back or becoming all of a sudden a technology company. So, we will go by a specific indication and by specific assets.
Rajan Sharma: Okay, that makes sense. Thank you.
Operator: Thank you. There are no further questions at this time. I would like to hand back over to Thomas Lingelbach, CEO for final remarks.
Thomas Lingelbach: This one I hand over to my friend, Josh.
Joshua Drumm: Yes. All right, well, thank you, everybody for your time and participation today. Please note, an archived version of today’s webcast will be made available later today. And a PDF of the slides presented during today’s call is already accessible on the company’s Web site. We look forward to a productive 2023 and with welcoming you back for our next conference call in the not so distant future. Thank you and enjoy the rest of your day.
Operator: That does conclude our conference for today. Thank you for participating. You may all disconnect.
